
    
      This is pivotal phase III study to evaluate the efficacy of nitazoxanide 600 mg BID compared
      to placebo to treat hospitalized patients with non-critical COVID-19.

      The aim is to demonstrate a decrease in hospital related complications among patients who are
      hospitalized with moderate COVID-19 by treating them with nitazoxanide BID 600 mg for 7 days
      on top of standard care compared to placebo on top of standar care..

      Therefore, patients hospitalized with confirmed diagnosis of COVID-19 will be randomized to
      receive either nitazoxanide 600 mg BID or Placebo.
    
  